Royalty Pharma plc (RPRX)
NASDAQ: RPRX · IEX Real-Time Price · USD
28.14
-0.19 (-0.67%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Royalty Pharma Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Royalty Pharma stock have an average target of 41.8, with a low estimate of 28 and a high estimate of 51. The average target predicts an increase of 48.54% from the current stock price of 28.14.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Royalty Pharma stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy Maintains $48 → $51 | Buy | Maintains | $48 → $51 | +81.24% | Jul 11, 2024 |
| UBS | UBS | Strong Buy → Hold Downgrades $28 | Strong Buy → Hold | Downgrades | $28 | -0.50% | Jun 3, 2024 |
| B of A Securities | B of A Securities | Strong Buy Maintains $40 → $38 | Strong Buy | Maintains | $40 → $38 | +35.04% | Apr 12, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $45 → $42 | Buy | Maintains | $45 → $42 | +49.25% | Feb 20, 2024 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $56 → $50 | Strong Buy | Maintains | $56 → $50 | +77.68% | Feb 20, 2024 |
Financial Forecast
Revenue This Year
2.65B
from 2.35B
Increased by 12.68%
Revenue Next Year
2.93B
from 2.65B
Increased by 10.40%
EPS This Year
3.95
from 2.53
Increased by 55.96%
EPS Next Year
4.46
from 3.95
Increased by 13.08%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 2.9B | 3.4B | 3.8B | 3.0B | 3.2B |
| Avg | 2.7B | 2.9B | 3.3B | 2.9B | 3.1B |
| Low | 2.3B | 2.5B | 2.7B | 2.8B | 3.0B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 21.6% | 27.2% | 28.9% | -7.4% | 8.1% |
| Avg | 12.7% | 10.4% | 11.8% | -10.0% | 5.0% |
| Low | -2.5% | -6.2% | -7.1% | -13.6% | 0.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 4.41 | 4.92 | 5.55 | 6.21 | 7.06 |
| Avg | 3.95 | 4.46 | 4.93 | 6.03 | 6.85 |
| Low | 3.32 | 3.94 | 4.14 | 5.79 | 6.59 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 74.3% | 24.8% | 24.5% | 25.8% | 17.0% |
| Avg | 56.0% | 13.1% | 10.6% | 22.2% | 13.7% |
| Low | 31.3% | -0.2% | -7.3% | 17.4% | 9.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.